GLP-1 RAs Efficacious for Weight Loss in Overweight, Obesity Without Diabetes
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 7, 2025 -- For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online Jan. 7 in the Annals of Internal Medicine.
Areesha Moiz, from McGill University in Montreal, and colleagues examined the efficacy and safety of GLP-1 RAs and co-agonists for obesity treatment among adults without diabetes in a systematic review of placebo-controlled randomized controlled trials (RCTs) in otherwise healthy adults with overweight or obesity. Twenty-six RCTs, with 15,491 participants and 12 agents (three commercially available and nine premarket), were included.
The researchers found that tirzepatide (15 mg once weekly), semaglutide (2.4 mg once weekly), and liraglutide (3.0 mg once daily) resulted in weight loss of up to 17.8, 13.9, and 5.8 percent after 72, 68, and 26 weeks of therapy, respectively, compared with placebo. Retatrutide (12 mg once weekly) resulted in weight loss of up to 22.1 percent after 48 weeks; other novel single and combination GLP-1 agents were also efficacious. Adverse events were frequent (80 to 97 percent versus 63 to 100 percent for GLP-1 RA versus placebo); most were gastrointestinal-related, including nausea, vomiting, diarrhea, and constipation.
"Our results support the use of GLP-1 RAs and co-agonists for the treatment of overweight or obesity among patients without diabetes," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 -- In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy...
Long-Term Obesity Linked to Expression of Aging Biomarkers
THURSDAY, July 17, 2025 -- Long-term obesity is associated with the expression of biomarkers denoting antagonistic and integrative aging hallmarks in adults aged 28 to 31 years...
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
THURSDAY, July 17, 2025 -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.